|
| The promise of dual targeting Akt/mTOR signaling in lethal prostate cancer |
|
https://doi.org/10.18632/oncotarget.771
Nicolas Floc'h, and Cory Abate-Shen
|
| 1483-1484 |
|
| PI3Kβ downstream of GPCRs – crucial partners in oncogenesis |
|
https://doi.org/10.18632/oncotarget.787
Hashem A Dbouk, Oscar Vadas, Roger L Williams, and Jonathan M Backer
|
| 1485-1486 |
|
| Endotrophin – Linking Obesity with Aggressive Tumor Growth |
|
https://doi.org/10.18632/oncotarget.796
Jiyoung Park, and Philipp E. Scherer
|
| 1487-1488 |
|
| Attacking MALT1 for ABCDLBCL therapy |
|
https://doi.org/10.18632/oncotarget.794
Daniel Krappmann
|
| 1489-1490 |
|
| mTOR inhibitor efficacy is determined by the eIF4E/4EBP ratio |
|
https://doi.org/10.18632/oncotarget.799
Tommy Alain, Nahum Sonenberg, and Ivan Topisirovic
|
| 1491-1492 |
|
| Targeting Lymphomas Through MALT1 Inhibition |
|
https://doi.org/10.18632/oncotarget.819
Lorena Fontan, and Ari Melnick
|
| 1493-1494 |
|
| PU1 is a tumor suppressor for B cell malignancies |
|
https://doi.org/10.18632/oncotarget.800
Yutaka Okuno, and Hiromichi Yuki
|
| 1495-1496 |
|
| Tumorinfiltrating macrophages cancer stem cells and therapeutic responses |
|
https://doi.org/10.18632/oncotarget.792
Roheena Z Panni, David C Linehan, and David G DeNardo
|
| 1497-1498 |
|
| Coordinate PI3K pathway and Bcl2 family disruption in AML |
|
https://doi.org/10.18632/oncotarget.809
Prithviraj Bose, Mohamed Rahmani, and Steven Grant
|
| 1499-1500 |
|
| Targeting Tumor Stroma: Exploiting Apoptotic Priming |
|
https://doi.org/10.18632/oncotarget.830
Joachim C. Mertens, and and Gregory J. Gores
|
| 1501-1502 |
|
| The Maintenance of Epigenetic States by p53: The Guardian of the Epigenome |
|
https://doi.org/10.18632/oncotarget.780
Arnold J. Levine, and Benjamin Greenbaum
|
| 1503-1504 |
|
| Advances in Targeting Signal Transduction Pathways |
|
https://doi.org/10.18632/oncotarget.802
James Andrew McCubrey, Linda S Steelman, William H Chappell, Lin Sun, Nicole M Davis, Stephen L Abrams, Richard A Franklin, Lucio Cocco, Camilla Evangelisti, Francesca Chiarini, Alberto M Martelli, Massimo Libra, Saverio Candido, Grazia Malaponte, Maria C Mazzarino, Paolo Fagone, Marco Donia, Ferdinando Nicoletti, Jerry Polesel, Renato Talamini, Jorg Basecke, Sanja Mijatovic, Danijela Maksimovic-Ivanic, Michele Milella, Agostino Tafuri, Joanna Dulińska-Litewka, Piotr Laidler, Antonio B D'Assoro, Lyudmyla Drobot, Kazuo Umezawa, Giuseppe Montalto, Melchiorre Cervello, and Zoya N Demidenko
|
| 1505-1521 |
|
| Recent progress in genetics of aging senescence and longevity: focusing on cancerrelated genes |
|
https://doi.org/10.18632/oncotarget.889
Albert E. Berman, Olga V. Leontieva, Venkatesh Natarajan, James A. McCubrey, Zoya N. Demidenko, and Mikhail A. Nikiforov
|
| 1522-1532 |
|
| Identification and Characterization of a Novel Chemotype MEK Inhibitor Able to Alter the Phosphorylation State of MEK1/2 |
|
https://doi.org/10.18632/oncotarget.747
Takayuki Yoshida, Junya Kakegawa, Takayuki Yamaguchi, Yoshiji Hantani, Nobuyuki Okajima, Toshiyuki Sakai, Yoshihiro Watanabe, and Motonao Nakamura
|
| 1533-1545 |
|
| Downregulation of Sox7 is associated with aberrant activation of Wnt/βcatenin signaling in endometrial cancer |
|
https://doi.org/10.18632/oncotarget.667
David W Chan, Celia SL Mak, Thomas HY Leung, Karen KL Chan, and Hextan YS Ngan
|
| 1546-1556 |
|
| All tyrosine kinase inhibitorresistant chronic myelogenous cells are highly sensitive to Ponatinib |
|
https://doi.org/10.18632/oncotarget.692
Ophelie Cassuto, Maeva Dufies, Arnaud Jacquel, Alexandre Puissant, Clemence Ginet, Amine Hamouda, Frederic Luciano, Guillaume Robert, Jean-Michel Karsenti, Laurence Legros, Jill Patrice Cassuto, Pascal Lenain, and Patrick Auberger
|
| 1557-1565 |
|
| PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes |
|
https://doi.org/10.18632/oncotarget.716
Filip Janku, Jennifer J. Wheler, Aung Naing, Vanda M. T. Stepanek, Gerald S. Falchook, Siqing Fu, Ignacio Garrido-Laguna, Apostolia M. Tsimberidou, Sarina A. Piha-Paul, Stacy L. Moulder, J. Jack Lee, Rajyalakshmi Luthra, David S. Hong, and Razelle Kurzrock
|
| 1566-1575 |
|
| FAK is a critical regulator of neuroblastoma liver metastasis |
|
https://doi.org/10.18632/oncotarget.732
Sora Lee, Jingbo Qiao, Pritha Paul, Kathleen L. O’Connor, Mark Evers, and Dai H. Chung
|
| 1576-1587 |
|
| Smallmolecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem and progenitor cells in acute myeloid leukemia AML |
|
https://doi.org/10.18632/oncotarget.733
Harald Herrmann, Katharina Blatt, Junwei Shi, Karoline V. Gleixner, Sabine Cerny-Reiterer, Leonhard Müllauer, Christopher R. Vakoc, Wolfgang R. Sperr, Hans-Peter Horny, James E. Bradner, Johannes Zuber, and Peter Valent
|
| 1588-1599 |
|
| Autophagyrelated gene 12 ATG12 is a novel determinant of primary resistance to HER2targeted therapies: Utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment |
|
https://doi.org/10.18632/oncotarget.742
SÃlvia CufÃ, Alejandro Vazquez-Martin, Ceistina Oliveras-Ferraros, Bruna Corominas-Faja, Ander Urruticoechea, Begoña Martin-Castillo, and Javier A Menendez
|
| 1600-1614 |
|
| A combination of temsirolimus an allosteric mTOR inhibitor with clofarabine as a new therapeutic option for patients with acute myeloid leukemia |
|
https://doi.org/10.18632/oncotarget.762
Francesca Chiarini, Annalisa Lonetti, Gabriella Teti, Ester Orsini, Daniela Bressanin, Alessandra Cappellini, Francesca Ricci, Pier Luigi Tazzari, Andrea Ognibene, Mirella Falconi, Pasqualepaolo Pagliaro, Ilaria Iacobucci, Giovanni Martinelli, Sergio Amadori, James A McCubrey, and Alberto M Martelli
|
| 1615-1628 |
|
| Development of an orallyadministrative MELKtargeting inhibitor that suppresses the growth of various types of human cancer |
|
https://doi.org/10.18632/oncotarget.790
Suyoun Chung, Hanae Suzuki, Takashi Miyamoto, Naofumi Takamatsu, Ayako Tatsuguchi, Koji Ueda, Kyoko Kijima, Yusuke Nakamura, and Yo Matsuo
|
| 1629-1640 |
|
| Lin28b Promotes Head and Neck Cancer Progression via Modulation of the InsulinLike Growth Factor Survival Pathway |
|
https://doi.org/10.18632/oncotarget.785
Nehad M Alajez, Wei Shi, Dennis Wong, Michelle Lenarduzzi, John Waldron, Ilan Weinreb, and Fei-Fei Liu
|
| 1641-1652 |
|
| Stress Response of Glioblastoma Cells Mediated by miR175p Targeting PTEN and the Passenger Strand miR173p Targeting MDM2 |
|
https://doi.org/10.18632/oncotarget.810
Haoran Li, and Burton B Yang
|
| 1653-1668 |
|
| STAT5 triggers BCRABL1 mutation by mediating ROS production in chronic myeloid leukaemia |
|
https://doi.org/10.18632/oncotarget.806
Wolfgang Warsch, Eva Grundschober, Angelika Berger, Lars Gille, Sabine Cerny-Reiterer, Anca-Sarmiza Tigan, Andrea Hoelbl-Kovacic, Peter Valent, Richard Moriggl, and Veronika Sexl
|
| 1669-1687 |
|
| Simalikalactone E SkE a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway |
|
https://doi.org/10.18632/oncotarget.791
Guillaume Robert, Valérie Jullian, Arnaud Jacquel, Clémence Ginet, Maeva Dufies, Stephanie Torino, Anaïs Pottier, Frederic Peyrade, Sophie Tartare-Deckert, Geneviève Bourdy, Eric Deharo, and Patrick Auberger
|
| 1688-1699 |
|
| Gene expressionbased risk score in diffuse large Bcell lymphoma |
|
https://doi.org/10.18632/oncotarget.807
Caroline Bret, Bernard Klein, and Jérôme Moreaux
|
| 1700-1710 |
|
| Common drugs and treatments for cancer and agerelated diseases: revitalizing answers to NCI’s provocative questions |
|
https://doi.org/10.18632/oncotarget.890
Mikhail V. Blagosklonny
|
| 1711-1724 |
